Find a Clinical Trial
Filter
Dompe' Reparixin study
COVID-19
All genders
18+
Recruiting now
Department of Medicine, Division of Geographic Medicine + Infectious Diseases
AN2 EBO301 MAC Study
Mycobacterial disease
All genders
18+
Recruiting now
Department of Medicine, Division of Geographic Medicine + Infectious Diseases
Moderna mRNA 1273 study
COVID-19
All genders
0-12
Recruiting now
Department of Medicine, Division of Geographic Medicine + Infectious Diseases
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer (OPERA-01)
Breast cancer, Locally advanced and metastatic breast cancer
All genders
18+
Recruiting now
Cancer Center
Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin (VOLGA)
Bladder cancer
All genders
18+
Recruiting now
Department of Medicine, Cancer Center
Letermovir for secondary prophylaxis for CMV disease in solid organ transplant recipients
Cytomegalovirus infection
All genders
18-75
Recruiting now
Department of Medicine, Division of Geographic Medicine + Infectious Diseases
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy
All genders
18+
Recruiting now
Department of Medicine, Division of Hematology/Oncology, Cancer Center
Breast Cancer Database
Breast cancer
All genders
18+
Recruiting now
Department of Medicine, Division of Hematology/Oncology, Cancer Center
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy (CAMBRIA-1)
All genders
18+
Recruiting now
Cancer Center
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
Breast cancer
All genders
18+
Recruiting now
Cancer Center